Although the existing evidence in HFpEF is compelling, further trials seem warranted, particularly with respect to the effects of GLP-1 RAs on clinical outcomes and, possibly, in broader patient populations, such as patients with HFrEF or those without obesity.
The legitimate medical uses of intravenous infusions may not need a Therapeutic Use Exemption in certain settings (hospital treatment, surgical procedures or clinical investigations)
Understanding GLP-1 Receptor Agonists GLP-1 receptor agonists, more commonly known as glucagon-like peptide-1 receptor agonists, are FDA-approved medications for diabetes, but theyve become msot popular for their significant weight loss benefits
Since GLP-1 medications can reduce your appetite, you may be eating less overall, which can make it harder to meet your daily nutrient needs
Too often, prior authorization requirements delay access to essential medicationseven for long-standing, stable therapies or simple dose changes ordered by a physician